EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
×
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
NASDAQ:CERS

Cerus - CERS Stock Forecast, Price & News

$3.65
-0.05 (-1.35%)
(As of 11/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.62
$3.74
50-Day Range
$3.38
$4.10
52-Week Range
$3.25
$7.20
Volume
955,932 shs
Average Volume
1.65 million shs
Market Capitalization
$647.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Cerus MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
64.4% Upside
$6.00 Price Target
Short Interest
Healthy
3.50% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.51mentions of Cerus in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$48,875 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.22) to ($0.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.74 out of 5 stars

Medical Sector

892nd out of 1,038 stocks

Surgical & Medical Instruments Industry

94th out of 103 stocks

CERS stock logo

About Cerus (NASDAQ:CERS) Stock

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

Receive CERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter.

CERS Stock News Headlines

Comparing TearLab (OTCMKTS:TEAR) and Cerus (NASDAQ:CERS)
Comparing Cerus (NASDAQ:CERS) & Medigus (NASDAQ:MDGS)
Cerus (NASDAQ:CERS) Shares Gap Down to $3.82
Cerus's Return On Capital Employed Overview
Cerus (NASDAQ: CERS)
Cerus Corporation (CERS)
See More Headlines
Receive CERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter.

CERS Company Calendar

Last Earnings
11/02/2021
Today
11/29/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/28/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:CERS
CUSIP
15708510
Employees
631
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+64.4%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-54,380,000.00
Pretax Margin
-24.09%

Debt

Sales & Book Value

Annual Sales
$130.86 million
Book Value
$0.50 per share

Miscellaneous

Free Float
164,416,000
Market Cap
$647.59 million
Optionable
Optionable
Beta
1.11

Social Links


Key Executives

  • Mr. William M. Greenman (Age 55)
    Pres, CEO & Director
    Comp: $1.25M
  • Dr. Laurence M. CorashDr. Laurence M. Corash (Age 78)
    Co-Founder & Chief Scientific Officer
    Comp: $697.77k
  • Mr. Kevin D. Green (Age 50)
    VP of Fin. & CFO
    Comp: $698.15k
  • Mr. Vivek K. JayaramanMr. Vivek K. Jayaraman (Age 47)
    Chief Operating Officer
    Comp: $845.3k
  • Dr. Richard J. Benjamin (Age 62)
    Chief Medical Officer
    Comp: $718.64k
  • Ms. Lori L. Roll
    VP of Admin. & Corp. Sec.
  • Mr. Matthew M. Notarianni
    Sr. Director of Investor Relations
  • Ms. Chrystal N. MenardMs. Chrystal N. Menard (Age 51)
    Chief Legal Officer & Gen. Counsel
  • Lainie Corten
    VP of Global Marketing
  • Ms. Carol M. MooreMs. Carol M. Moore (Age 72)
    Sr. VP of Regulatory Affairs, Quality & Clinical













CERS Stock - Frequently Asked Questions

What is Cerus' stock price forecast for 2023?

0 equities research analysts have issued 1-year price objectives for Cerus' stock. Their CERS share price forecasts range from $6.00 to $6.00. On average, they expect the company's share price to reach $6.00 in the next year. This suggests a possible upside of 63.5% from the stock's current price.
View analysts price targets for CERS
or view top-rated stocks among Wall Street analysts.

How have CERS shares performed in 2022?

Cerus' stock was trading at $6.81 at the beginning of 2022. Since then, CERS stock has decreased by 46.1% and is now trading at $3.67.
View the best growth stocks for 2022 here
.

When is Cerus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our CERS earnings forecast
.

How were Cerus' earnings last quarter?

Cerus Co. (NASDAQ:CERS) posted its quarterly earnings data on Tuesday, November, 2nd. The biotechnology company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.03. The biotechnology company earned $36.13 million during the quarter, compared to the consensus estimate of $31.60 million. Cerus had a negative net margin of 24.24% and a negative trailing twelve-month return on equity of 48.32%. During the same quarter last year, the company posted ($0.08) EPS.

What guidance has Cerus issued on next quarter's earnings?

Cerus updated its FY 2022 earnings guidance on Thursday, November, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $160.00 million-$162.00 million, compared to the consensus revenue estimate of $173.50 million.

What is William M. (Obi) Greenman's approval rating as Cerus' CEO?

15 employees have rated Cerus Chief Executive Officer William M. (Obi) Greenman on Glassdoor.com. William M. (Obi) Greenman has an approval rating of 35% among the company's employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cerus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA).

What is Cerus' stock symbol?

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Who are Cerus' major shareholders?

Cerus' stock is owned by a number of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (9.52%), BlackRock Inc. (6.89%), Vanguard Group Inc. (5.89%), Sumitomo Mitsui Trust Holdings Inc. (4.14%), State Street Corp (2.75%) and Senvest Management LLC (2.50%). Insiders that own company stock include Carol Moore, Chrystal Menard, Daniel N Swisher Jr, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson, Timothy L Moore, Vivek K Jayaraman, Vivek K Jayaraman and William Mariner Greenman.
View institutional ownership trends
.

How do I buy shares of Cerus?

Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cerus' stock price today?

One share of CERS stock can currently be purchased for approximately $3.67.

How much money does Cerus make?

Cerus (NASDAQ:CERS) has a market capitalization of $651.13 million and generates $130.86 million in revenue each year. The biotechnology company earns $-54,380,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis.

How many employees does Cerus have?

The company employs 631 workers across the globe.

How can I contact Cerus?

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The official website for the company is www.cerus.com. The biotechnology company can be reached via phone at (925) 288-6000, via email at ir@cerus.com, or via fax at 925-288-6001.

This page (NASDAQ:CERS) was last updated on 11/29/2022 by MarketBeat.com Staff